NR1H4 and Other metabolic disease: Resveratrol reduces TMAO levels through down-regulation of the enterohepatic farnesoid X receptor-fibroblast growth factor (FXR) axis, indicating that the gut microbiota is a potent target for personalized medicine interventions in diminishing metabolic disease development risk (24, 25).